Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/15/2019 | 05:09pm EDT

By Dave Sebastian

Gilead Science Inc. (GILD) and Galapagos NV said Thursday that its marketing authorization application for filgotinib, a treatment for rheumatoid arthritis, is being evaluated by the European Medicines Agency.

The application is based on 24-week data from the treatment's phase 3 clinical trials that demonstrated improvements in arthritis signs and symptoms, the companies said.

The EMA is a European Union agency that evaluates and approves medicinal products for its 28 members as well as Norway, Iceland and Liechtenstein.

Gilead has announced plans to submit a new drug application to the Food and Drug Administration for the treatment by the end of the year.

Gilead said in July it will pay $5.1 billion to boost its stake in Galapagos and gain rights outside Europe to the Belgian biotechnology company's treatments in development.

Write to Dave Sebastian at dave.sebastian@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
GALAPAGOS 1.10% 146.85 Delayed Quote.82.29%
GALAPAGOS ADR 1.35% 161.08 Delayed Quote.75.58%
GILEAD SCIENCES 0.70% 66.42 Delayed Quote.6.19%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
09/16A Plan to Fight Hep C -- WSJ
DJ
09/12GILEAD SCIENCES : Ex-dividend day for
FA
09/09GILEAD SCIENCES : and the Elton John AIDS Foundation Launch RADIAN Initiative to..
BU
08/29GILEAD SCIENCES : An amendment to a SC 13D filing
PU
08/29AGENUS : Triggers 3rd Milestone in its Collaboration with Gilead
AQ
08/29GILEAD SCIENCES : Report
CO
08/27GILEAD SCIENCES INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/26GILEAD SCIENCES : to Present at the Morgan Stanley Global Healthcare Conference ..
BU
08/26GILEAD SCIENCES : Alberta Provides Access to Biktarvy® for the Treatment of HIV
AQ
08/26GILEAD SCIENCES : And galapagos complete closing of their transformative researc..
AQ
More news
Financials (USD)
Sales 2019 22 314 M
EBIT 2019 11 591 M
Net income 2019 4 272 M
Debt 2019 3 023 M
Yield 2019 3,79%
P/E ratio 2019 18,9x
P/E ratio 2020 11,6x
EV / Sales2019 3,91x
EV / Sales2020 3,76x
Capitalization 84 118 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,52  $
Last Close Price 66,42  $
Spread / Highest target 43,0%
Spread / Average Target 21,2%
Spread / Lowest Target -9,67%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES6.19%84 118
VERTEX PHARMACEUTICALS7.49%45 783
REGENERON PHARMACEUTICALS-20.78%32 375
GENMAB29.51%13 425
NEUROCRINE BIOSCIENCES, INC.41.20%9 234
HUALAN BIOLOGICAL ENGINEERING INC--.--%6 523